DURHAM — The chief scientific officer and chief financial officer of biotechnology company Aerie Pharmaceuticals Inc. have recently sold more than $5 million in shares, according to security filings.
CSO Casey Kopczynski sold 9,330 shares of the Durham-based company on Monday at a price of $60.43 per share and $1,670 shares at a price of $61.34 per share worth $666,000, according to a filing with the securities and exchange commission.
He still owns more than 136,000 shares of the company valued at approximately $8.37 million.
Kopczynski also sold $660,000 in Aerie stock last month.
In addition, Chief Financial Officer Richard Rubino sold $4 million in shares last week. He sold 49,500 shares at a price of $60.18, 500 shares at $61.01, 16,497 shares at $60.36 and another 108 shares at a price of $61.01, according to another SEC filing.
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company. The company focuses on the discovery, development and commercialization of therapies for patients with glaucoma, retinal diseases and other eye diseases.
Kopczynski co-founded Aerie Pharmaceuticals in 2005 and has served as its chief scientific officer since its formation.
Previously, he was the managing partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies from 2002 to 2005.
He worked as the vice president of research at Ercole Biotech Inc. from 2003 to 2004, an early stage company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases.
Aerie Pharmaceuticals shares closed Monday at $59.28, down $2.27 from the previous day’s close.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
